TAX2 for advanced solid tumors that came back
Part of Cancer clinical trials.
This trial tests a new drug called TAX2 for people with certain advanced cancers (ovarian, colorectal, pancreatic, or melanoma) that have stopped responding to standard treatments. The goal is to see if TAX2 is safe and can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of these cancers that has come back or spread: ovarian cancer (except mucinous type), colorectal cancer, pancreatic cancer (except neuroendocrine tumors), or melanoma (skin cancer).
- You have already tried standard treatments for your cancer, and they are no longer working.
- You are willing to have a small tissue sample (biopsy) taken before and during treatment (or can provide a recent sample).
- You are generally well enough to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This Phase 1 study tests IMC-002 in people with advanced cancers that did not respond to standard therapy. It may help by trying a new immune-targeting drug approach when other options have failed.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Hear when a new Solid Tumor Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.